Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses).
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000740:Anemia / Q000139:chemically induced; D001254:Astrocytoma / Q000188:drug therapy; D001772:Blood Cell Count; D001792:Blood Platelets; D002277:Carcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D003537:Cystadenoma / Q000188:drug therapy; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D009369:Neoplasms / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy; D011160:Porfiromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D012208:Rhabdomyosarcoma / Q000188:drug therapy
D011160:Porfiromycin